Commercial Products

Product Name	Indication	Commercial Partner	Milestones
	Niemann-Pick disease type C in patients age two and older View full prescribing information	-	Zevra Therapeutics’ MIPLYFFA® (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C View Press Release

MIPLYFFA is approved in the U.S. for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.

For more information visit www.miplyffa-hcp.com

Product Name	Indication	Commercial Partner	Milestones
	Certain Urea Cycle Disorders* View full prescribing information	-	Zevra acquires Acer Therapeutics in 2023 View Press Release

*OLPRUVA (sodium phenylbutyrate) for oral suspension approved in the U.S. for the treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

For more information visit www.olpruvahcp.com

OLPRUVA is a registered trademark of Acer Therapeutics Inc., a wholly owned subsidiary of Zevra Therapeutics, Inc.